LUMOBRY

Posology One drop in the affected eye(s) every 6 – 8 hours, no more than four times daily. A reduction in ocular redness should occur within 5-15 minutes. 4). Method of administration Ocular use. Lumobry should be applied in the affected eye(s) with pressing nasolacrimal duct and closing the eyelids for 2 minutes.

These procedures enable to reduce the systemic absorption of the drug what result in a decrease in systemic side effects occurrence and an increase in local (ocular) activity. If Lumobry is used with other topical ophthalmic medicinal product, the 15- minute interval should be maintained.

Hands should be thoroughly washed before and after using the product. 4).

The frequency of occurrence of side effects was arranged as specified below:

Very Common: (≥ 1/10) Common: (≥ 1/100, < 1/10) Uncommon: (≥ 1/1,000, < 1/100) Rare: (≥ 1/10,000, < 1/1 000) Very rare: (< 1/10,000) Frequency unknown (cannot be estimated from the available data). 25 mg/ml, eye drops was shown to be similar to the safety profile of the vehicle.

2). 9). 2%), it may be assumed that the risk of serious side effects related to the CNS and peripheral tissues should also be significantly lower for Lumobry product. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via theYellow Card Scheme. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

25 mg/ml, eye drops, solution is for intermittent or occasional use only. g. allergic reaction, dry eye disease) should be primarily treated. A reduction in ocular redness should occur within 5-15 minutes. However, if the condition worsens or persists for more than 72 hours, the use of the product should be discontinued and the patient should be reevaluated.

Eye irritation or redness caused by a serious ocular disease, such as infection, foreign body or damage to the cornea, acute glaucoma or iritis requires immediate medical attention. ). Such activity may result in the increase of disease symptoms and thus special caution should be applied in such patients treated with the product.

Simultaneous use of other ophthalmic topical drugs If Lumobry is used with other topical ophthalmic medicinal product simultaneously, the 15-minute interval should be maintained. Hepatic / Renal Impairment Brimonidine has not been studied in patients with hepatic or renal impairment, therefore special caution should be used in treating such patients.

25 mg/ml, eye drops, solution should not be used in paediatric patients. Excipients-specific The medicinal product contains benzalkonium chloride and may cause eye irritation. Benzalkonium chloride is known to discolour soft contact lenses.

The contact of the drug with contact lenses should be avoided. Contact lenses should be removed prior the application and 15-minute interval maintained before lenses reinsertion.

1. Lumobry should not be used in the following conditions: - prolonged hyperaemia of the eye - prolonged irritation of the eye - ocular infections – mucopurulent discharge from the ocular tissues - eye pain - vision changes/disturbances